A Pacemaker to Control BP:
\nNew therapy targeting uncontrolled hypertension using a pacemaker!.
\nMedscape. April 23 ,2025.
\nAtrioventricular interval modulation (AVIM) therapy designed to provide immediate relief to patients with uncontrolled hypertension.<\/p>\n
Article Summary:
\n1. FDA Breakthrough Designation: The US FDA granted Breakthrough Device Designation to Orchestra BioMed for its new therapy targeting uncontrolled hypertension using a pacemaker.
\n2. What is AVIM?: The therapy, called AVIM (Atrioventricular Interval Modulation) delivered through dual-chamber pacemakers, modulates AV interval & heart rhythm to lower blood pressure and influence the autonomic nervous system.modulate the autonomic nervous system.
\n3. Target Patients: For the time being AVIM is designed for high risk patients with uncontrolled hypertension especially those who don\u2019t respond well to or can\u2019t tolerate antihypertensive medications.
\n4. Estimated Population: Over 7.7 million patients in the US may be eligible for this therapy, according to Orchestra BioMed.
\n5. Clinical Evidence: A clinical trial (MODERATO II) showed significant reductions in both ambulatory and office systolic blood pressure.
\n6. Ongoing Trial:
\nA larger trial (BACKBEAT), in partnership with Medtronic, is ongoing.
\nThe manufacturer aims to expand AVIM beyond pacemaker patients, offering a consistent, device-based alternative to daily medications!.<\/p>\n